MedTrace Logo

Psilocybin Brain Stimulation and Imaging Pilot Study

NCT06835699 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-04-20

No results posted yet for this study

Summary

This open-label pilot psilocybin administration study investigates the influence of psilocybin on brain function and cognitive control functions in clinically and psychiatrically healthy volunteers. Participants will undergo experimental drug administration sessions after careful screening and preparation. Participants will also have brain activity measured using electroencephalogram (EEG) also during non-invasive brain stimulation using Transcranial Magnetic Stimulation (TMS).

Conditions

  • Healthy Volunteers

Interventions

DRUG

Psilocybin 25 mgs

All participants will be administered 25 mg psilocybin and undergo TMS

DEVICE

TMS

All participants will be administered 25 mg psilocybin and undergo TMS

Sponsors & Collaborators

Principal Investigators

  • Ceyda Sayali, PhD · Johns Hopkins University

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-18
Primary Completion
2026-08-31
Completion
2026-08-31
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06835699 on ClinicalTrials.gov